BTIG Research restated their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $843.00 target price on the stock. Several other research firms also recently issued reports on PRAX. Truist Financial raised Praxis Precision Medicines to a […]